Randomized, blinded trial of vitamin D                         3                          for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

Alice C. Shapiro; Susan A. Adlis; Kim Robien; Mark N. Kirstein; Shuang Liang; Sara A. Richter; Rachel E. Lerner

doi:10.1007/s10549-016-3710-6

Randomized, blinded trial of vitamin D ₃ for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

Alice C. Shapiro, Susan A. Adlis, Kim Robien, Mark N. Kirstein, Shuang Liang, Sara A. Richter, Rachel E. Lerner

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

The purpose of the study was to evaluate the efficacy and safety of vitamin D ₃ at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D ₃ . We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women ≥18 years with stages I–IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale ≥1.5] were admitted. Following randomization, 116 patients had a run-in period of 1 month on 600 IU D ₃ , then began the randomized assignment to either 600 IU D ₃ (n = 56) or 4000 IU D ₃ (n = 57) daily for 6 months. The primary endpoint was a change in AIMSS from baseline (after 1 month run-in) on the BCPT-MS (general MS pain, joint pain, muscle stiffness, range for each question: 0 = not at all to 4 = extremely). Groups had no statistically significant differences demographically or clinically. There were no discernable differences between the randomly allocated treatment groups at 6 months in measures of AIMSS, pharmacokinetics of anastrozole and letrozole, serum levels of reproductive hormones, or adverse events. We found no significant changes in AIMSS measures between women who took 4000 IU D ₃ daily compared with 600 IU D ₃ . The 4000 IU D ₃ did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (≥30 ng/mL) and safety (<50 ng/mL).

Original language	English (US)
Pages (from-to)	501-512
Number of pages	12
Journal	Breast Cancer Research and Treatment
Volume	155
Issue number	3
DOIs	https://doi.org/10.1007/s10549-016-3710-6
State	Published - Feb 1 2016

Bibliographical note

Funding Information:
Research relating to this analysis was co-funded by Grants from the National Cancer Institute and the National Institutes of Health Office of Dietary Supplements (R21 CA149934) and the Park Nicollet Institute and Park Nicollet Foundation. This work was supported in part by NIHP30CA77598, using the following University of Minnesota Masonic Cancer Center Resource: Clinical Pharmacology and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH UL1TR000114). The study was registered in Clinical Trials.gov (NCT01509079) and conducted under IND #114046. Trial Registration clinicaltrials.gov, identifier: NCT01509079.

Publisher Copyright:
© 2016, Springer Science+Business Media New York.

Keywords

Aromatase inhibitors
Arthralgias
Breast cancer
Vitamin D

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/s10549-016-3710-6

http://europepmc.org/articles/pmc5260816

Find It

Find It at U of M Libraries

Cite this

Shapiro, A. C., Adlis, S. A., Robien, K., Kirstein, M. N., Liang, S., Richter, S. A., & Lerner, R. E. (2016). Randomized, blinded trial of vitamin D ₃ for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Research and Treatment, 155(3), 501-512. https://doi.org/10.1007/s10549-016-3710-6

Randomized, blinded trial of vitamin D ₃ for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). / Shapiro, Alice C.; Adlis, Susan A.; Robien, Kim et al.
In: Breast Cancer Research and Treatment, Vol. 155, No. 3, 01.02.2016, p. 501-512.

Research output: Contribution to journal › Article › peer-review

@article{5b184d9a24654d40897b0ca9627fa824,

title = "Randomized, blinded trial of vitamin D 3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)",

abstract = " The purpose of the study was to evaluate the efficacy and safety of vitamin D 3 at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D 3 . We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women ≥18 years with stages I–IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale ≥1.5] were admitted. Following randomization, 116 patients had a run-in period of 1 month on 600 IU D 3 , then began the randomized assignment to either 600 IU D 3 (n = 56) or 4000 IU D 3 (n = 57) daily for 6 months. The primary endpoint was a change in AIMSS from baseline (after 1 month run-in) on the BCPT-MS (general MS pain, joint pain, muscle stiffness, range for each question: 0 = not at all to 4 = extremely). Groups had no statistically significant differences demographically or clinically. There were no discernable differences between the randomly allocated treatment groups at 6 months in measures of AIMSS, pharmacokinetics of anastrozole and letrozole, serum levels of reproductive hormones, or adverse events. We found no significant changes in AIMSS measures between women who took 4000 IU D 3 daily compared with 600 IU D 3 . The 4000 IU D 3 did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (≥30 ng/mL) and safety (<50 ng/mL).",

keywords = "Aromatase inhibitors, Arthralgias, Breast cancer, Vitamin D",

author = "Shapiro, {Alice C.} and Adlis, {Susan A.} and Kim Robien and Kirstein, {Mark N.} and Shuang Liang and Richter, {Sara A.} and Lerner, {Rachel E.}",

note = "Funding Information: Research relating to this analysis was co-funded by Grants from the National Cancer Institute and the National Institutes of Health Office of Dietary Supplements (R21 CA149934) and the Park Nicollet Institute and Park Nicollet Foundation. This work was supported in part by NIHP30CA77598, using the following University of Minnesota Masonic Cancer Center Resource: Clinical Pharmacology and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH UL1TR000114). The study was registered in Clinical Trials.gov (NCT01509079) and conducted under IND #114046. Trial Registration clinicaltrials.gov, identifier: NCT01509079. Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = feb,

day = "1",

doi = "10.1007/s10549-016-3710-6",

language = "English (US)",

volume = "155",

pages = "501--512",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - Randomized, blinded trial of vitamin D 3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)

AU - Shapiro, Alice C.

AU - Adlis, Susan A.

AU - Robien, Kim

AU - Kirstein, Mark N.

AU - Liang, Shuang

AU - Richter, Sara A.

AU - Lerner, Rachel E.

N1 - Funding Information: Research relating to this analysis was co-funded by Grants from the National Cancer Institute and the National Institutes of Health Office of Dietary Supplements (R21 CA149934) and the Park Nicollet Institute and Park Nicollet Foundation. This work was supported in part by NIHP30CA77598, using the following University of Minnesota Masonic Cancer Center Resource: Clinical Pharmacology and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH UL1TR000114). The study was registered in Clinical Trials.gov (NCT01509079) and conducted under IND #114046. Trial Registration clinicaltrials.gov, identifier: NCT01509079. Publisher Copyright: © 2016, Springer Science+Business Media New York.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The purpose of the study was to evaluate the efficacy and safety of vitamin D 3 at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D 3 . We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women ≥18 years with stages I–IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale ≥1.5] were admitted. Following randomization, 116 patients had a run-in period of 1 month on 600 IU D 3 , then began the randomized assignment to either 600 IU D 3 (n = 56) or 4000 IU D 3 (n = 57) daily for 6 months. The primary endpoint was a change in AIMSS from baseline (after 1 month run-in) on the BCPT-MS (general MS pain, joint pain, muscle stiffness, range for each question: 0 = not at all to 4 = extremely). Groups had no statistically significant differences demographically or clinically. There were no discernable differences between the randomly allocated treatment groups at 6 months in measures of AIMSS, pharmacokinetics of anastrozole and letrozole, serum levels of reproductive hormones, or adverse events. We found no significant changes in AIMSS measures between women who took 4000 IU D 3 daily compared with 600 IU D 3 . The 4000 IU D 3 did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (≥30 ng/mL) and safety (<50 ng/mL).

AB - The purpose of the study was to evaluate the efficacy and safety of vitamin D 3 at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D 3 . We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women ≥18 years with stages I–IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale ≥1.5] were admitted. Following randomization, 116 patients had a run-in period of 1 month on 600 IU D 3 , then began the randomized assignment to either 600 IU D 3 (n = 56) or 4000 IU D 3 (n = 57) daily for 6 months. The primary endpoint was a change in AIMSS from baseline (after 1 month run-in) on the BCPT-MS (general MS pain, joint pain, muscle stiffness, range for each question: 0 = not at all to 4 = extremely). Groups had no statistically significant differences demographically or clinically. There were no discernable differences between the randomly allocated treatment groups at 6 months in measures of AIMSS, pharmacokinetics of anastrozole and letrozole, serum levels of reproductive hormones, or adverse events. We found no significant changes in AIMSS measures between women who took 4000 IU D 3 daily compared with 600 IU D 3 . The 4000 IU D 3 did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (≥30 ng/mL) and safety (<50 ng/mL).

KW - Aromatase inhibitors

KW - Arthralgias

KW - Breast cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84959105978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959105978&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3710-6

DO - 10.1007/s10549-016-3710-6

M3 - Article

C2 - 26868123

AN - SCOPUS:84959105978

SN - 0167-6806

VL - 155

SP - 501

EP - 512

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -